Cotempla XR-ODT (Methylphenidate) Patent Expiration, LOE Window & CMS Spending
Cotempla XR-ODT (Methylphenidate) by Neos Therapeutics: FDA Orange Book LOE 2038-01-25, 1 AB generics, $10.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Neos Therapeutics |
| FDA Application & Pathway | N205489 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2038-01-25 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $10.1M |
| 2024 Medicare Part D Spend | $192K |
| 2024 Medicaid Spend | $9.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |